Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration

Open access
Rojas, Julio C., Wang, Ping, Staffaroni, Adam M., Heller, Carolin, Cobigo, Yann, Wolf, Amy, Goh, Sheng-Yang M., Ljubenkov, Peter A., Heuer, Hilary W., Fong, Jamie C., Taylor, Joanne B., Veras, Eliseo, Song, Linan, Jeromin, Andreas, Hanlon, David, Yu, Lili, Khinikar, Arvind, Sivasankaran, Rajeev, Kieloch, Agnieszka, Valentin, Marie-Anne, Karydas, Anna M., Mitic, Laura L., Pearlman, Rodney, Kornak, John, Kramer, Joel H., Miller, Bruce L., Kantarci, Kejal, Knopman, David S., Graff-Radford, Neill, Petrucelli, Leonard, Rademakers, Rosa, Irwin, David J., Grossman, Murray, Ramos, Eliana Marisa, Coppola, Giovanni, Mendez, Mario F., Bordelon, Yvette, Dickerson, Bradford C., Ghoshal, Nupur, Huey, Edward D., Mackenzie, Ian R., Appleby, Brian S., Domoto-Reilly, Kimiko, Hsiung, Ging-Yuek R., Toga, Arthur W., Weintraub, Sandra, Kaufer, Daniel I., Kerwin, Diana, Litvan, Irene, Onyike, Chiadikaobi U., Pantelyat, Alexander, Roberson, Erik D., Tartaglia, Maria C., Foroud, Tatiana, Chen, Weiping, Czerkowicz, Julie, Graham, Danielle L., van Swieten, John C., Borroni, Barbara, Sanchez-Valle, Raquel, Moreno, Fermin, Laforce, Robert, Graff, Caroline, Synofzik, Matthis, Galimberti, Daniela, Rowe, James B., Masellis, Mario, Finger, Elizabeth, Vandenberghe, Rik, de Mendonça, Alexandre, Tagliavini, Fabrizio, Santana, Isabel, Ducharme, Simon, Butler, Chris R., Gerhard, Alexander, Levin, Johannes, Danek, Adrian, Otto, Markus, Sorbi, Sandro, Cash, David M., Convery, Rhian S., Bocchetta, Martina, Foiani, Martha, Greaves, Caroline V., Peakman, Georgia, Russell, Lucy, Swift, Imogen, Todd, Emily, Rohrer, Jonathan D., Boeve, Bradley F., Rosen, Howard J., Boxer, Adam L., on behalf of the ALLFTD and GENFI consortia · 2021 · Neurology

Abstract

OBJECTIVE: We tested the hypothesis that plasma neurofilament light chain (NfL) identifies asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)-causing mutations at risk of disease progression. METHODS: mutation carriers and noncarriers from the same families were classified by disease severity (asymptomatic, prodromal, and full phenotype) using the CDR Dementia Staging Instrument plus behavior and language domains from the National Alzheimer's Disease Coordinating Center FTLD module (CDR+NACC-FTLD). Linear mixed-effect models related NfL to clinical variables. RESULTS: = 0.035). Plasma NfL discriminated symptomatic from asymptomatic mutation carriers or those with prodromal disease (original cutoff: 13.6 pg/mL, 87.5% sensitivity, 82.7% specificity; validation cutoff: 19.8 pg/mL, 87.4% sensitivity, 84.3% specificity). Higher baseline NfL correlated with worse longitudinal CDR+NACC-FTLD sum of boxes scores, neuropsychological function, and atrophy, regardless of genotype or disease severity, including asymptomatic mutation carriers. CONCLUSIONS: Plasma NfL identifies asymptomatic carriers of FTLD-causing mutations at short-term risk of disease progression and is a potential tool to select participants for prevention clinical trials. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02372773 and NCT02365922. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in carriers of FTLD-causing mutations, elevation of plasma NfL predicts short-term risk of clinical progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000011848

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Baseline Plasma NfL Chain Concentrations by Clinical Phenotype (A) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (B) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Phenotypes are based on clinical diagnosis and did not rely on severity scales. Only the original cohort included clinically diagnosed prodromal disease (mild behavioral impairment [MBI] or mild cognitive impairment [MCI]). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. bvFTD = behavioral variant frontotemporal dementia; CBS = corticobasal syndrome; FTD/ALS = frontotemporal dementia with amyotrophic lateral sclerosis; NfL = neurofilament light chain; PPA = primary progressive aphasia (nonfluent or semantic). *Compared to normal. **Compared to normal and MCI, p < 0.05.
Figure 1 Baseline Plasma NfL Chain Concentrations by Clinical Phenotype (A) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (B) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Phenotypes are based on clinical diagnosis and did not rely on severity scales. Only the original cohort included clinically diagnosed prodromal disease (mild behavioral impairment [MBI] or mild cognitive impairment [MCI]). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. bvFTD = behavioral variant frontotemporal dementia; CBS = corticobasal syndrome; FTD/ALS = frontotemporal dementia with amyotrophic lateral sclerosis; NfL = neurofilament light chain; PPA = primary progressive aphasia (nonfluent or semantic). *Compared to normal. **Compared to normal and MCI, p < 0.05.CC BY · PubMed Central
Figure 2 Baseline Plasma NfL Concentrations by Disease Severity and Diagnostic Performance (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Severity was determined by the CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module (CDR+NACC-FTLD). (A and D) Boxplots show plasma neurofilament light chain (NfL) concentrations in asymptomatic carriers (i.e., CDR+NACC-FTLD score 0), those with mild behavioral or cognitive impairment (mild behavioral impairment/mild cognitive impairment [MBI/MCI], CDR+NACC-FTLD score 0.5), and patients with full phenotypes (CDR+NACC-FTLD score ≥1). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. (B and E) Receiver operating characteristic (ROC) curves show that plasma NfL was a good discriminator between individuals with full phenotype and those either asymptomatic or with MBI/MCI. (C and F) Proportion of patients with low or high plasma NfL concentrations, determined by the ROC curve, is presented for each disease severity. AUC = area under the curve.
Figure 2 Baseline Plasma NfL Concentrations by Disease Severity and Diagnostic Performance (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Severity was determined by the CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module (CDR+NACC-FTLD). (A and D) Boxplots show plasma neurofilament light chain (NfL) concentrations in asymptomatic carriers (i.e., CDR+NACC-FTLD score 0), those with mild behavioral or cognitive impairment (mild behavioral impairment/mild cognitive impairment [MBI/MCI], CDR+NACC-FTLD score 0.5), and patients with full phenotypes (CDR+NACC-FTLD score ≥1). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. (B and E) Receiver operating characteristic (ROC) curves show that plasma NfL was a good discriminator between individuals with full phenotype and those either asymptomatic or with MBI/MCI. (C and F) Proportion of patients with low or high plasma NfL concentrations, determined by the ROC curve, is presented for each disease severity. AUC = area under the curve.CC BY · PubMed Central
Figure 3 Plasma NfL Concentrations by Disease Severity in Each Genotype Group (A–C) Original cohort. (D–F) Validation cohort. MBI/MCI = mild behavioral or cognitive impairment (CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module score 0.5); C90rf72 = chromosome 9 open reading frame 72; GRN = progranulin; MAPT = microtubule-associated protein tau; NC = noncarrier; NfL = neurofilament light chain.
Figure 3 Plasma NfL Concentrations by Disease Severity in Each Genotype Group (A–C) Original cohort. (D–F) Validation cohort. MBI/MCI = mild behavioral or cognitive impairment (CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module score 0.5); C90rf72 = chromosome 9 open reading frame 72; GRN = progranulin; MAPT = microtubule-associated protein tau; NC = noncarrier; NfL = neurofilament light chain.CC BY · PubMed Central
Figure 4 Baseline Plasma NfL Concentrations According to Conversion Status by Follow-Up Severity was determined with the CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module (CDR+NACC-FTLD). (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. (A and D) Median baseline neurofilament light chain (NfL) concentrations were higher in asymptomatic mutation carriers (CDR+NACC-FTLD score 0) who progressed to either mild behavioral or cognitive impairment (MBI/MCI; CDR+NACC-FTLD score 0.5) or full phenotype (CDR+NACC-FTLD score ≥1) on follow-up. (B and E) A similar trend was observed in individuals who had MBI/MCI at baseline and when all participants (asymptomatic mutation carriers and those with MBI/MCI) were combined (C and F). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. Circles = asymptomatic; triangles = MBI/MCI; blue = chromosome 9 open reading frame 72(C9orf72) mutation carriers; red = microtubule-associated protein tau (MAPT) mutation carriers; yellow = progranulin (GRN) mutation carriers;.
Figure 4 Baseline Plasma NfL Concentrations According to Conversion Status by Follow-Up Severity was determined with the CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module (CDR+NACC-FTLD). (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. (A and D) Median baseline neurofilament light chain (NfL) concentrations were higher in asymptomatic mutation carriers (CDR+NACC-FTLD score 0) who progressed to either mild behavioral or cognitive impairment (MBI/MCI; CDR+NACC-FTLD score 0.5) or full phenotype (CDR+NACC-FTLD score ≥1) on follow-up. (B and E) A similar trend was observed in individuals who had MBI/MCI at baseline and when all participants (asymptomatic mutation carriers and those with MBI/MCI) were combined (C and F). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. Circles = asymptomatic; triangles = MBI/MCI; blue = chromosome 9 open reading frame 72(C9orf72) mutation carriers; red = microtubule-associated protein tau (MAPT) mutation carriers; yellow = progranulin (GRN) mutation carriers;.CC BY · PubMed Central
Figure 5 Prediction of Clinical Progression by Plasma NfL in Familial Frontotemporal Lobar Degeneration (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Figure shows the results of models using data from all genotypes in each severity group. In the original cohort, patients with high (red; ≥13.6 pg/mL) baseline plasma neurofilament light chain (NfL) showed worse clinical scores at 2 years compared to patients with low (blue; <13.6 pg/mL) NfL, which was supported by NfL level–by–time interaction. This differential predictive effect by NfL level was observed regardless of disease severity, including asymptomatic carriers. Similar results were observed in the validation cohort with a cut point value of 19.8 pg/mL. CDR+NACC-FTLDsb = CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module sum of boxes score. *Between-group contrast at that time point, p < 0.05.
Figure 5 Prediction of Clinical Progression by Plasma NfL in Familial Frontotemporal Lobar Degeneration (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Figure shows the results of models using data from all genotypes in each severity group. In the original cohort, patients with high (red; ≥13.6 pg/mL) baseline plasma neurofilament light chain (NfL) showed worse clinical scores at 2 years compared to patients with low (blue; <13.6 pg/mL) NfL, which was supported by NfL level–by–time interaction. This differential predictive effect by NfL level was observed regardless of disease severity, including asymptomatic carriers. Similar results were observed in the validation cohort with a cut point value of 19.8 pg/mL. CDR+NACC-FTLDsb = CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module sum of boxes score. *Between-group contrast at that time point, p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 4

  1. Schwab R, England A. Projection Technique for Evaluating Surgery in Parkinson's Disease. London;ES Livingston; 1969.
  2. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test–Adult Version-Manual.San Antonio; Psychological Corp; 2000.
  3. ALLFTLD Study. ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration: A Multisite Research Consortium [online]. Available at: allftd.org/. Accessed May 5, 2020.
  4. Food and Drug Administration. Early Alzheimer's Disease: Developing Drugs for Treatment. Guidance for Industry: Silver Spring, MD: US Department of Health and Human Services, Center for Drug Evaluation and Research; 2018.

Cited by

See all 120

Metadata

Authors
Rojas, J. C., Wang, P., Staffaroni, A. M., Heller, C., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Ljubenkov, P. A., Heuer, H. W., Fong, J. C., Taylor, J. B., Veras, E., Song, L., Jeromin, A., Hanlon, D., Yu, L., Khinikar, A., Sivasankaran, R., Kieloch, A., Valentin, M.-A., Karydas, A. M., Mitic, L. L., Pearlman, R., Kornak, J., Kramer, J. H., Miller, B. L., Kantarci, K., Knopman, D. S., Graff-Radford, N., Petrucelli, L., Rademakers, R., Irwin, D. J., Grossman, M., Ramos, E. M., Coppola, G., Mendez, M. F., Bordelon, Y., Dickerson, B. C., Ghoshal, N., Huey, E. D., Mackenzie, I. R., Appleby, B. S., Domoto-Reilly, K., Hsiung, G.-Y. R., Toga, A. W., Weintraub, S., Kaufer, D. I., Kerwin, D., Litvan, I., Onyike, C. U., Pantelyat, A., Roberson, E. D., Tartaglia, M. C., Foroud, T., Chen, W., Czerkowicz, J., Graham, D. L., van Swieten, J. C., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce, R., Graff, C., Synofzik, M., Galimberti, D., Rowe, J. B., Masellis, M., Finger, E., Vandenberghe, R., de Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C. R., Gerhard, A., Levin, J., Danek, A., Otto, M., Sorbi, S., Cash, D. M., Convery, R. S., Bocchetta, M., Foiani, M., Greaves, C. V., Peakman, G., Russell, L., Swift, I., Todd, E., Rohrer, J. D., Boeve, B. F., Rosen, H. J., Boxer, A. L., & consortia, O. B. O. T. A. A. G.
Affiliations
  • Northwestern University (US)
  • University of California, San Francisco (US)
  • From the University of California, San Francisco (J.C.R., P.W., A.M.S., Y.C., A.W., S.-Y.M.G., P.A.L., H.W.H., J.C.F., J.B.T., A.M.K., L.L.M., J.K., J.H.K., B.L.M., H.J.S., A.L.B.); UK Dementia Research Centre (C.H., D.M.C., R.S.C., M.B., M.F., C.V.G., G.P., L.R., I.S., E.T., J.D.R.), UCL Institute of Neurology, Queen Square, London; Quanterix Corp (E.V., L.S., A.J., D.H.), Lexington; Novartis Institutes for Biomedical Research Inc (L.Y., A. Khinikar, R.S.), Cambridge, MA; Novartis Pharma AG (A....
  • Novartis (Switzerland) (CH)
Corresponding author
Rojas, Julio C.
Venue
Neurology
Published
2021-05-04
Volume
96
Issue
18
Pages
e2296-e2312
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3147351247
Cited by
106
References
50
Citations by year
2026: 15 · 2025: 25 · 2024: 19 · 2023: 21 · 2022: 15 · 2021: 11
FWCI
11.83
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Brunel University Research Archive (BURA) (Brunel University London) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by)
  • Lirias (submittedVersion, other-oa)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • DZNE Pub (submittedVersion, other-oa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, public-domain)
  • Apollo
  • DRYAD (public-domain)
Funders
  • Larry L. Hillblom Foundation (2018-A-025-FEL)
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Biogen
  • BrightFocus Foundation
  • University of Pennsylvania
  • Wellcome Trust (103838/Z/14/Z)
  • Little Family Foundation
  • EU Joint Programme – Neurodegenerative Disease Research (2019-02248, 739510)
  • Ionis Pharmaceuticals
  • Brain Research UK (202021-32)
  • National Brain Appeal (RCN 290173)
  • Alzheimer's Society (AS-JF-19a-004-517)
  • TauRx Pharmaceuticals
  • Alzheimer Society
  • National Institute for Health and Care Research (BRC1215-20014, BRC149/NS/MH)
  • Wolfson Foundation
  • Deutsche Forschungsgemeinschaft (EXC 2145, EXC 2145SyNergy, 390857198)
  • Cambridge University Hospitals (146281)
  • Eisai
  • Karolinska Institutet
  • Stockholms Läns Landsting
  • Vetenskapsrådet (2018-, 2015-02926, 2018-02754)
  • UK Dementia Research Institute
  • National Institutes of Health (AG016976, NS092089)
  • Genentech
  • Avid Radiopharmaceuticals
  • Canadian Institutes of Health Research
  • Medical Research Council (MR/M023664/1, MR/T046015/1, MR/M008525/1, MR/M009041/1)
  • Alzheimer Society of B.C.
  • NIHR Cambridge Biomedical Research Centre
  • National Institute on Aging (AG 016976, K23AG059888, K23AG059891, U01AG016976, K23AG061253, R01AG062268, P01AG066597, U24 AG21886, NS092089, U01AG045390, AG045390, AG021886, K24AG045333, U19AG063911, P01AG019724, P30AG066507, P30AG062422, U24AG021886)
  • National Institute of Mental Health (R01MH120794)
  • National Institute of Neurological Disorders and Stroke (U01NS102035, U54NS092089)
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
plasma neurofilament light chain, familial frontotemporal lobar degeneration, asymptomatic mutation carriers, disease progression prediction, biomarkers, neurodegeneration
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Predictive Value of Tests, Cohort Studies, Biomarkers, Neurofilament Proteins, Disease Progression, Young Adult, Frontotemporal Lobar Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. https://app.cochat.ai/papers/10.1212/wnl.0000000000011848
The paper
Rojas, J. C., Wang, P., Staffaroni, A. M., Heller, C., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Ljubenkov, P. A., Heuer, H. W., Fong, J. C., Taylor, J. B., Veras, E., Song, L., Jeromin, A., Hanlon, D., Yu, L., Khinikar, A., Sivasankaran, R., Kieloch, A., . . . consortia, O. B. O. T. A. A. G. (2021). Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology. https://doi.org/10.1212/wnl.0000000000011848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.